8-K: bioAffinity Technologies Reports Strong Q2 Sales Growth

bioAffinity Technologies announced over 200% year-over-year sales growth for its CyPath Lung diagnostic in Q2 2026, driven by increased physician adoption and repeat utilization.

Summary

• bioAffinity Technologies reported significant commercial sales acceleration for its noninvasive lung cancer diagnostic, CyPath Lung, in the second quarter of 2026.
• Sales volume for Q2 2026 increased by more than 200% year-over-year and over 30% compared to the first quarter of 2026.
• The growth is attributed to increased utilization by existing clients and a 155% rise in ordering physician offices compared to Q2 2025.
• The company has now performed nearly 3,000 CyPath Lung tests since its commercial launch.
• bioAffinity Technologies is advancing initiatives including a large-scale clinical study, expansion into oncology for monitoring lung cancer survivors, and developing diagnostic tests for asthma and COPD.
• The company expects to report its Q2 2026 financial results in August.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report due to significant year-over-year and sequential sales growth, coupled with positive physician adoption trends and promising future development initiatives.

Positives

• CyPath Lung sales volume grew by more than 200% year-over-year in Q2 2026.
• Sales volume increased by over 30% from Q1 2026 to Q2 2026.
• The number of physician offices ordering CyPath Lung increased by 155% compared to Q2 2025.
• Repeat utilization by physicians indicates the test is becoming a routine part of clinical decision-making.
• Nearly 3,000 CyPath Lung tests have been performed since commercial launch.
• CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value (NPV) in a published clinical trial for high-risk patients.

Risks

• The company's ability to successfully commercialize CyPath Lung.
• Risks related to the regulatory environment for laboratory developed tests (LDTs).
• Potential for actual results to differ materially from forward-looking statements due to various risks and uncertainties.

Future Outlook

The company is advancing multiple initiatives including a large-scale longitudinal clinical study, expansion into oncology for monitoring lung cancer survivors, and developing diagnostic tests for asthma and COPD. The company expects to report its financial results for the second quarter of 2026 in August.

Management Comments

• "We are at the forefront of a positive change in clinical practice. We believe it is the result of expanding physician familiarity and accumulating clinical evidence as more patients are evaluated with CyPath Lung and benefit from CyPath Lung-guided care."
• "The most encouraging trend goes beyond onboarding new practices the fact is, physicians who try CyPath Lung appreciate its benefits and continue to use it. Repeat utilization suggests the test is becoming part of routine clinical decision-making for patients with indeterminate pulmonary nodules."
• "The number of patients diagnosed with indeterminate pulmonary nodules is expected to grow significantly over the next several years with expanded lung cancer screening and incidental findings from other procedures. The challenge is determining which patients require immediate invasive evaluation and which can be safely monitored. CyPath Lung is designed to provide clinicians with an objective, noninvasive tool that complements imaging and helps them make more informed decisions while reducing unnecessary procedures and patient anxiety."
• "We are building on the success of CyPath Lung to develop noninvasive tests designed to ensure asthma and COPD patients are matched with the most effective treatment for their type of lung disease. We continue to develop our automated flow cytometry platform that supports an expanding number of diagnostic tests that we believe can lead to improved lung health for millions of people."

Industry Context

StockSavvy.ai notes that bioAffinity Technologies' strong sales growth for its CyPath Lung diagnostic aligns with the increasing demand for noninvasive early-stage cancer detection methods and the broader trend of personalized medicine in the biotechnology and healthcare sectors. The company's focus on lung cancer, asthma, and COPD addresses significant unmet needs in respiratory disease management.

Stakeholder Impact

• Shareholders: Potential for increased valuation and future returns due to strong sales growth and product development.
• Patients: Access to a noninvasive diagnostic tool for early lung cancer detection, potentially leading to better treatment outcomes and reduced anxiety.
• Physicians: Availability of a tool to aid in decision-making for patients with indeterminate pulmonary nodules, potentially reducing unnecessary invasive procedures.
• Healthcare System: Potential for cost savings through reduced unnecessary invasive procedures and earlier, more effective treatment of lung cancer.

Next Steps

• Report Q2 2026 financial results in August.
• Conduct a large-scale longitudinal clinical study for CyPath Lung.
• Expand into oncology for monitoring lung cancer survivors.
• Develop diagnostic tests for asthma and COPD.
• Continue developing the automated flow cytometry platform.

Key Dates

Recommendation

The filing indicates exceptionally strong sales growth for CyPath Lung, significantly exceeding prior periods and demonstrating accelerating market adoption. The high accuracy metrics, positive physician feedback, and clear pipeline of future developments suggest substantial growth potential and a strong competitive position in the noninvasive diagnostics market.

Keywords

CyPath Lung, lung cancer diagnostic, noninvasive test, bioAffinity Technologies, sales growth, biotechnology, pulmonary nodules, early detection, flow cytometry, AI